Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.

Shah V, Nowinski S, Levi D, Shinomiya I, Kebaier Ep Chaabouni N, Gillett C, Grigoriadis A, Graham TA, Roylance R, Simpson MA, Pinder SE, Sawyer EJ.

Breast Cancer Res. 2017 Jan 17;19(1):7. doi: 10.1186/s13058-016-0789-y.

2.

Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ.

Manders JB, Kuerer HM, Smith BD, McCluskey C, Farrar WB, Frazier TG, Li L, Leonard CE, Carter DL, Chawla S, Medeiros LE, Guenther JM, Castellini LE, Buchholz DJ, Mamounas EP, Wapnir IL, Horst KC, Chagpar A, Evans SB, Riker AI, Vali FS, Solin LJ, Jablon L, Recht A, Sharma R, Lu R, Sing AP, Hwang ES, White J; Study investigators and study participants..

Ann Surg Oncol. 2017 Mar;24(3):660-668. doi: 10.1245/s10434-016-5583-7. Epub 2016 Oct 4.

3.

Tumor characteristics of ductal carcinoma in situ of breast visualized on [F-18] fluorodeoxyglucose-positron emission tomography/computed tomography: Results from a retrospective study.

Fujioka T, Kubota K, Toriihara A, Machida Y, Okazawa K, Nakagawa T, Saida Y, Tateishi U.

World J Radiol. 2016 Aug 28;8(8):743-9. doi: 10.4329/wjr.v8.i8.743.

4.

Genetic predisposition to ductal carcinoma in situ of the breast.

Petridis C, Brook MN, Shah V, Kohut K, Gorman P, Caneppele M, Levi D, Papouli E, Orr N, Cox A, Cross SS, Dos-Santos-Silva I, Peto J, Swerdlow A, Schoemaker MJ, Bolla MK, Wang Q, Dennis J, Michailidou K, Benitez J, González-Neira A, Tessier DC, Vincent D, Li J, Figueroa J, Kristensen V, Borresen-Dale AL, Soucy P, Simard J, Milne RL, Giles GG, Margolin S, Lindblom A, Brüning T, Brauch H, Southey MC, Hopper JL, Dörk T, Bogdanova NV, Kabisch M, Hamann U, Schmutzler RK, Meindl A, Brenner H, Arndt V, Winqvist R, Pylkäs K, Fasching PA, Beckmann MW, Lubinski J, Jakubowska A, Mulligan AM, Andrulis IL, Tollenaar RA, Devilee P, Le Marchand L, Haiman CA, Mannermaa A, Kosma VM, Radice P, Peterlongo P, Marme F, Burwinkel B, van Deurzen CH, Hollestelle A, Miller N, Kerin MJ, Lambrechts D, Floris G, Wesseling J, Flyger H, Bojesen SE, Yao S, Ambrosone CB, Chenevix-Trench G, Truong T, Guénel P, Rudolph A, Chang-Claude J, Nevanlinna H, Blomqvist C, Czene K, Brand JS, Olson JE, Couch FJ, Dunning AM, Hall P, Easton DF, Pharoah PD, Pinder SE, Schmidt MK, Tomlinson I, Roylance R, García-Closas M, Sawyer EJ.

Breast Cancer Res. 2016 Feb 17;18(1):22. doi: 10.1186/s13058-016-0675-7.

5.

Impact of Histopathological Factors, Patient History and Therapeutic Variables on Recurrence-free Survival after Ductal Carcinoma in Situ: 8-Year Follow-up and Questionnaire Survey.

van Mackelenbergh MT, Lindner CM, Heilmann T, Alkatout I, Elessawy M, Mundhenke C, Maass N, Schem C.

Geburtshilfe Frauenheilkd. 2016 Jan;76(1):46-52.

6.

Lentivirus-Mediated Short-Hairpin RNA Targeting Protein Phosphatase 4 Regulatory Subunit 1 Inhibits Growth in Breast Cancer.

Qi Y, Hu T, Li K, Ye R, Ye Z.

J Breast Cancer. 2015 Sep;18(3):218-24. doi: 10.4048/jbc.2015.18.3.218. Epub 2015 Sep 24. Erratum in: J Breast Cancer. 2016 Dec;19(4):467.

7.

Epigenetic Regulation of miRNAs and Breast Cancer Stem Cells.

Duru N, Gernapudi R, Eades G, Eckert R, Zhou Q.

Curr Pharmacol Rep. 2015 Jun 1;1(3):161-169.

8.

Molecular drivers of lobular carcinoma in situ.

Logan GJ, Dabbs DJ, Lucas PC, Jankowitz RC, Brown DD, Clark BZ, Oesterreich S, McAuliffe PF.

Breast Cancer Res. 2015 Jun 4;17:76. doi: 10.1186/s13058-015-0580-5. Review.

9.

Systematic review of postradiotherapy bronchiolitis obliterans organizing pneumonia in women with breast cancer.

Epler GR, Kelly EM.

Oncologist. 2014 Dec;19(12):1216-26. doi: 10.1634/theoncologist.2014-0041. Epub 2014 Oct 31. Review.

10.

Cardiovascular morbidity and mortality after treatment for ductal carcinoma in situ of the breast.

Boekel NB, Schaapveld M, Gietema JA, Rutgers EJ, Versteegh MI, Visser O, Aleman BM, van Leeuwen FE.

J Natl Cancer Inst. 2014 Aug 15;106(8). pii: dju156. doi: 10.1093/jnci/dju156. Print 2014 Aug.

11.

Trends in detection of invasive cancer and ductal carcinoma in situ at biennial screening mammography in Spain: a retrospective cohort study.

Román M, Rué M, Sala M, Ascunce N, Baré M, Baroja A, De la Vega M, Galcerán J, Natal C, Salas D, Sánchez-Jacob M, Zubizarreta R, Castells X; Cumulative False Positive Risk Group..

PLoS One. 2013 Dec 23;8(12):e83121. doi: 10.1371/journal.pone.0083121. eCollection 2013.

12.

Downregulation of miR-140 promotes cancer stem cell formation in basal-like early stage breast cancer.

Li Q, Yao Y, Eades G, Liu Z, Zhang Y, Zhou Q.

Oncogene. 2014 May 15;33(20):2589-600. doi: 10.1038/onc.2013.226. Epub 2013 Jun 10.

13.

Ductal carcinoma in situ: what the pathologist needs to know and why.

Bane A.

Int J Breast Cancer. 2013;2013:914053. doi: 10.1155/2013/914053. Epub 2013 Feb 6.

14.

Ductal carcinoma in situ of the breast: a surgical perspective.

Badruddoja M.

Int J Surg Oncol. 2012;2012:761364. doi: 10.1155/2012/761364. Epub 2012 Sep 4.

15.

Investigational Paradigms in Downscoring and Upscoring DCIS: Surgical Management Review.

Orsaria P, Granai AV, Venditti D, Petrella G, Buonomo O.

Int J Surg Oncol. 2012;2012:560493. doi: 10.1155/2012/560493. Epub 2012 May 16.

16.

Progression of Ductal Carcinoma in Situ from the Pathological Perspective.

Cunha PO, Ornstein M, Jones JL.

Breast Care (Basel). 2010 Aug;5(4):233-239. Epub 2010 Aug 23.

17.

Exogenous estrogen protects mice from the consequences of obesity and alcohol.

Holcomb VB, Hong J, Núñez NP.

Menopause. 2012 Jun;19(6):680-90. doi: 10.1097/gme.0b013e31823cf6ee.

18.

Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.

Bayraktar S, Elsayegh N, Gutierrez Barrera AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton J, Meric-Bernstam F, Hortobagyi GN, Albarracin CT, Arun B.

Cancer. 2012 Mar 15;118(6):1515-22. doi: 10.1002/cncr.26428. Epub 2011 Aug 25. Erratum in: Cancer. 2014 Mar 15;120(6):927.

19.

Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ.

Meyerson AF, Lessing JN, Itakura K, Hylton NM, Wolverton DE, Joe BN, Esserman LJ, Hwang ES.

Breast. 2011 Dec;20(6):529-33. doi: 10.1016/j.breast.2011.06.001. Epub 2011 Aug 16.

20.

Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.

Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, Land SR, Margolese RG, Swain SM, Costantino JP, Wolmark N.

J Natl Cancer Inst. 2011 Mar 16;103(6):478-88. doi: 10.1093/jnci/djr027. Epub 2011 Mar 11.

Supplemental Content

Support Center